Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.

J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21.

PMID:
19164213
2.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
3.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

PMID:
22039088
4.

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL.

Cancer. 2013 Feb 15;119(4):714-21. doi: 10.1002/cncr.27804. Epub 2012 Sep 12. Review.

5.

Cetuximab in the treatment of patients with colorectal cancer.

Garrett CR, Eng C.

Expert Opin Biol Ther. 2011 Jul;11(7):937-49. doi: 10.1517/14712598.2011.582464. Epub 2011 May 11. Review.

PMID:
21557708
6.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
7.

Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.

Barni S, Ghilardi M, Borgonovo K, Cabiddu M, Zaniboni A, Petrelli F.

Rev Recent Clin Trials. 2013 Jun;8(2):101-9. Review.

PMID:
23859115
8.

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.

Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q.

Eur J Cancer. 2010 Oct;46(15):2781-7. doi: 10.1016/j.ejca.2010.05.022. Epub 2010 Jun 25. Review.

PMID:
20580219
9.

Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 Apr 21;20(15):4208-19. doi: 10.3748/wjg.v20.i15.4208. Review.

10.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

11.

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.

Lyseng-Williamson KA.

Mol Diagn Ther. 2012 Oct;16(5):317-22. doi: 10.1007/s40291-012-0007-2. Review.

PMID:
23055389
12.

KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?

Hebbar M, Fournier P, Romano O.

Eur J Cancer Care (Engl). 2010 Mar;19(2):167-71. doi: 10.1111/j.1365-2354.2009.01134.x. Epub 2009 Aug 20. Review.

PMID:
19702696
13.

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.

Chen J, Ye Y, Sun H, Shi G.

Cancer Chemother Pharmacol. 2013 Jan;71(1):265-72. doi: 10.1007/s00280-012-2005-9. Epub 2012 Oct 23. Review.

PMID:
23090619
14.

Cetuximab in metastatic colorectal cancer.

Broadbridge VT, Karapetis CS, Price TJ.

Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25. Review.

PMID:
22594891
15.

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.

Mancl EE, Kolesar JM, Vermeulen LC.

Am J Health Syst Pharm. 2009 Dec 1;66(23):2105-12. doi: 10.2146/ajhp090036. Review.

PMID:
19923311
16.

Standard chemotherapy with cetuximab for treatment of colorectal cancer.

Li XX, Liang L, Huang LY, Cai SJ.

World J Gastroenterol. 2015 Jun 14;21(22):7022-35. doi: 10.3748/wjg.v21.i22.7022. Review.

17.

Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.

Wang L, Chen X, Li W, Sheng Z.

Anticancer Drugs. 2012 Feb;23(2):155-60. doi: 10.1097/CAD.0b013e32834c3256. Review.

PMID:
21955998
18.

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S1-5. doi: 10.1016/S0305-7372(10)70012-8. Review.

PMID:
21129603
19.

KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.

Wang HL, Lopategui J, Amin MB, Patterson SD.

Adv Anat Pathol. 2010 Jan;17(1):23-32. doi: 10.1097/PAP.0b013e3181c6962f. Review.

PMID:
20032635
20.

Integration of panitumumab into the treatment of colorectal cancer.

Gravalos C, Cassinello J, García-Alfonso P, Jimeno A.

Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. doi: 10.1016/j.critrevonc.2009.06.005. Epub 2009 Jul 17. Review.

PMID:
19616446

Supplemental Content

Support Center